Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Alios BioPharma General Information
Alios BioPharma developed AL-8176, an orally administered antiviral therapy for RSV that showed promising results in Phase 2 studies. In clinical trials, volunteers infected with RSV showed no symptoms within a day and a half of receiving the drug and completely lost the virus, while the placebo group had persistent virus and symptoms for several days.
Contact Information
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States
United States
Drug Pipeline
AL-8176
Phase 2Key Partnerships
Vertex Pharmaceuticals, Janssen Pharmaceutical Companies of Johnson & Johnson
Alios BioPharma Funding
No funding data available
To view Alios BioPharma's complete valuation and funding history, request access »